Evolocumab,[5] sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia.
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation; its inhibition thereby enhances the liver's ability to remove LDL-C, often colloquially referred to as "bad" cholesterol, from the blood.[6][7]
^Sheridan C (December 2013). "Phase 3 data for PCSK9 inhibitor wows". Nature Biotechnology. 31 (12): 1057–1058. doi:10.1038/nbt1213-1057. PMID 24316621. S2CID 34214247.
^"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^"Repatha- evolocumab injection, solution Repatha- evolocumab kit". DailyMed. U.S. National Library of Medicine. 6 May 2020. Retrieved 20 October 2020.
^World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
^Coppinger C, Movahed MR, Azemawah V, Peyton L, Gregory J, Hashemzadeh M (20 May 2022). "A Comprehensive Review of PCSK9 Inhibitors". Journal of Cardiovascular Pharmacology and Therapeutics. 27: 10742484221100107. doi:10.1177/10742484221100107. PMID 35593194. S2CID 248918656.
^Weinreich M, Frishman WH (2014). "Antihyperlipidemic therapies targeting PCSK9". Cardiology in Review. 22 (3): 140–146. doi:10.1097/CRD.0000000000000014. PMID 24407047. S2CID 2201087.
Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. Evolocumab...
(romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib). Amgen was established in Thousand Oaks in...
particle concentrations. The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the U.S. Food and...
or in pregnant women. Injectable antibodies against the protein PCSK9 (evolocumab, bococizumab, alirocumab) can reduce LDL cholesterol and have been shown...
early identification of FH and treatment with statins. Alirocumab and evolocumab, both monoclonal antibodies against PCSK9, are specifically indicated...
of 2017, no drug exists that is able to do this. 17 March A new drug, evolocumab, is shown to prevent heart attacks and strokes by dramatically cutting...